Interestingly, in contrast to the positive impact of early GA treatment, our results showed that APP/PS1 mice following GA injections in a pre-symptomatic stage of amyloid-deposition did not exhibit any beneficial effect on either cognitive performance or plaque load. Here, PSEN1 is linked to amyloidosis.